ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Does Lymph Node Dissection During Esophagectomy Impact the Long-Term Prognosis for Complete Responders After Neoadjuvant Therapy? A Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Patients with Esophageal Carcinoma: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Comparison of overall survival across treatment modalities for oesophageal, gastroesophageal, and gastric cancer: protocol for a systematic review and network meta-analysis.Systematic reviews · 2026Pooled it
- Assessing the impact of neoadjuvant chemotherapy and chemoradiotherapy on quality of life during treatment in esophageal cancer: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Pooled it
- Health-related quality of life in esophageal cancer: a state-of-the-art review of patient-reported outcomes and an evidence and gap map.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Pooled it
- Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.Signal transduction and targeted therapy · 2025Trial
- Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.Nature medicine · 2024Trial
- Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer.Clinical and translational radiation oncology · 2026Article
- Determining acceptable duration for chemoradiation of esophageal squamous cell carcinoma.Journal of the Chinese Medical Association : JCMA · 2026Article
- Article
- Neoadjuvant Therapy for Esophageal Cancer.Cancers · 2026Review
- Article
- Neoadjuvant chemoradiotherapy vs. direct surgery for locally advanced esophageal cancer: a meta-analysis.Frontiers in surgery · 2026Review
- Deep learning models based on CT predict prognosis in patients with locally advanced esophageal squamous cell carcinoma who received neoadjuvant immunotherapy and chemotherapy.Frontiers in immunology · 2026Article
- A meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally resectable esophageal cancer based on RCTs.Frontiers in oncology · 2026Review
- Prognostic Value of Tumor Regression Grade After Chemotherapy Versus Chemoradiotherapy in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Esophageal Adenocarcinoma.Annals of surgical oncology · 2025Article
- Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Translational cancer research · 2025Article
- Clinical efficacy of different neoadjuvant therapies for resectable esophageal squamous cell carcinoma.World journal of surgical oncology · 2025Article
- Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma.BMC cancer · 2025Article
- Definition and Predictors of Early Recurrence in Neoadjuvantly Treated Esophageal and Gastroesophageal Adenocarcinoma: a Dual-Center Retrospective Cohort Study.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 11 countries.
Funding
Abstract
purposeThe optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. PATIENTS AND
methodsAll, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158).
resultsIPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99),
conclusionNeoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.